Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.

Chu GC, Chung LWK, Gururajan M, Hsieh CL, Josson S, Nandana S, Sung SY, Wang R, Wu JB, Zhau HE.

Asian J Urol. 2019 Jan;6(1):65-81. doi: 10.1016/j.ajur.2018.11.003. Epub 2018 Nov 28. Review.

2.

microRNAs and Prostate Cancer.

Josson S, Chung LW, Gururajan M.

Adv Exp Med Biol. 2015;889:105-18. doi: 10.1007/978-3-319-23730-5_7.

3.

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.

4.

Targeting the tumor-stromal-immune cell axis.

Gururajan M, Josson S, Chung LW.

Oncoscience. 2015 Aug 11;2(9):743-4. eCollection 2015. No abstract available.

5.

miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.

Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW.

Clin Cancer Res. 2014 Dec 15;20(24):6559-69. doi: 10.1158/1078-0432.CCR-14-1784. Epub 2014 Oct 16.

6.

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW.

Oncogene. 2015 May 21;34(21):2690-9. doi: 10.1038/onc.2014.212. Epub 2014 Jul 28.

PMID:
25065597
7.

miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.

Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.

8.

MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.

Li X, Chen YT, Josson S, Mukhopadhyay NK, Kim J, Freeman MR, Huang WC.

PLoS One. 2013 Aug 9;8(8):e70987. doi: 10.1371/journal.pone.0070987. eCollection 2013.

9.

Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.

Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA, Zayzafoon M, Hu P, Zhau H, Berel D, Rogatko A, Chung LW.

PLoS One. 2013 Jul 10;8(7):e68366. doi: 10.1371/journal.pone.0068366. Print 2013.

10.

β2-Microglobulin-mediated signaling as a target for cancer therapy.

Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW.

Anticancer Agents Med Chem. 2014 Mar;14(3):343-52. Review.

11.

In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.

Liu CM, Hsieh CL, He YC, Lo SJ, Liang JA, Hsieh TF, Josson S, Chung LW, Hung MC, Sung SY.

PLoS One. 2013;8(1):e53795. doi: 10.1371/journal.pone.0053795. Epub 2013 Jan 16.

12.

Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer.

Pen CC, Liu CM, Lin CC, Lin CC, Hsieh TF, Josson S, He YC, Chung LW, Lin KL, Sung SY.

Chin J Physiol. 2012 Dec 31;55(6):390-7. doi: 10.4077/CJP.2012.BAA075.

13.

EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.

Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LW, Zhau HE, Wu D.

Oncogene. 2011 Dec 15;30(50):4941-52. doi: 10.1038/onc.2011.199. Epub 2011 May 30.

14.

β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.

Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW.

Cancer Res. 2011 Apr 1;71(7):2600-10. doi: 10.1158/0008-5472.CAN-10-3382. Epub 2011 Mar 22.

15.

miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes.

Xu Y, Fang F, Zhang J, Josson S, St Clair WH, St Clair DK.

PLoS One. 2010 Dec 22;5(12):e14356. doi: 10.1371/journal.pone.0014356.

16.

Tumor-Stromal Interactions Influence Radiation Sensitivity in Epithelial- versus Mesenchymal-Like Prostate Cancer Cells.

Josson S, Sharp S, Sung SY, Johnstone PA, Aneja R, Wang R, Gururajan M, Turner T, Chung LW, Yates C.

J Oncol. 2010;2010. pii: 232831. doi: 10.1155/2010/232831. Epub 2010 Jul 29.

17.

Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.

Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW.

Prostate. 2011 Feb 15;71(3):232-40. doi: 10.1002/pros.21237.

18.

MicroRNA 125b inhibition of B cell differentiation in germinal centers.

Gururajan M, Haga CL, Das S, Leu CM, Hodson D, Josson S, Turner M, Cooper MD.

Int Immunol. 2010 Jul;22(7):583-92. doi: 10.1093/intimm/dxq042. Epub 2010 May 23.

19.

Tumor-stroma co-evolution in prostate cancer progression and metastasis.

Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R.

Semin Cell Dev Biol. 2010 Feb;21(1):26-32. doi: 10.1016/j.semcdb.2009.11.016. Epub 2009 Dec 3. Review.

20.

RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity.

Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A, St Clair WH.

Cancer Res. 2009 Apr 15;69(8):3267-71. doi: 10.1158/0008-5472.CAN-08-4635. Epub 2009 Apr 7.

21.

SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation.

Xu Y, Fang F, St Clair DK, Sompol P, Josson S, St Clair WH.

Mol Cancer Ther. 2008 Aug;7(8):2367-76. doi: 10.1158/1535-7163.MCT-08-0238.

22.

Radiation modulation of microRNA in prostate cancer cell lines.

Josson S, Sung SY, Lao K, Chung LW, Johnstone PA.

Prostate. 2008 Nov 1;68(15):1599-606. doi: 10.1002/pros.20827.

23.
24.

RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.

Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH.

Oncogene. 2006 Mar 9;25(10):1554-9.

Supplemental Content

Loading ...
Support Center